Literature DB >> 25371486

Reply to Eschenauer et al.

Ravina Kullar1, James A McKinnell2, George Sakoulas3.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25371486      PMCID： PMC4809982          DOI： 10.1093/cid/ciu885

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  10 in total

1.  Calming the "perfect storm" in methicillin-resistant Staphylococcus aureus bacteremia: a call for a more balanced discussion.

Authors:  Gregory A Eschenauer; Jerod L Nagel; Christine J Kubin; Simon W Lam; Twisha S Patel; Brian A Potoski
Journal:  Clin Infect Dis       Date:  2014-11-03       Impact factor: 9.079

2.  Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.

Authors:  Kyle P Murray; Jing J Zhao; Susan L Davis; Ravina Kullar; Keith S Kaye; Paul Lephart; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2013-02-28       Impact factor: 9.079

Review 3.  Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.

Authors:  Ravina Kullar; James A McKinnell; George Sakoulas
Journal:  Clin Infect Dis       Date:  2014-07-21       Impact factor: 9.079

4.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

5.  Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.

Authors:  Carol L Moore; Paola Osaki-Kiyan; Nadia Z Haque; Mary Beth Perri; Susan Donabedian; Marcus J Zervos
Journal:  Clin Infect Dis       Date:  2011-11-21       Impact factor: 9.079

6.  Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  George Sakoulas; George M Eliopoulos; Jeff Alder; Claudie Thauvin Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  D P Levine; B S Fromm; B R Reddy
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

8.  Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus.

Authors:  George Sakoulas; Cheryl Y Okumura; Wdee Thienphrapa; Joshua Olson; Poochit Nonejuie; Quang Dam; Abhay Dhand; Joseph Pogliano; Michael R Yeaman; Mary E Hensler; Arnold S Bayer; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2013-12-03       Impact factor: 4.599

9.  Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Ravina Kullar; Susan L Davis; Keith S Kaye; Donald P Levine; Jason M Pogue; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2013-01       Impact factor: 4.705

10.  Investigator initiated trials (IITs).

Authors:  Viraj Suvarna
Journal:  Perspect Clin Res       Date:  2012-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.